The HDAC2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population carrying targeted disruption of the HDAC2 gene. Derived from the A-549 human lung adenocarcinoma line, this loss-of-function model enables study of histone deacetylase 2 biology without clonal selection. The polyclonal format captures diverse editing events, providing a robust system for population-level assays requiring gene knockout. These cells are suitable for transient and stable transfection, functional complementation, and high-throughput screening.
The parental A-549 cell line was established from lung adenocarcinoma tissue of a 58-year-old Caucasian male and serves as a model of alveolar type II pneumocytes. These epithelial cells exhibit adherent growth and retain key oncogenic alterations relevant to non-small cell lung carcinoma. Frequently used in respiratory epithelial and cancer signaling studies, A-549 provides a clinically pertinent background for HDAC2 knockout, with well-characterized transcriptional and proteomic profiles that aid interpretation of CRISPR-mediated perturbations.
HDAC2 is a class I histone deacetylase that removes acetyl groups from lysine residues on histone H3 and H4, and non-histone substrates including p53, STAT3, and FOXP3. This activity promotes chromatin compaction and transcriptional repression through corepressor complexes containing HDAC1, SIN3A, RbAp48, and CoREST. HDAC2 is regulated by upstream transcription factors SP1, MYC, E2F1, and p53, and its activity is modulated by casein kinase 2 phosphorylation and SUMOylation. Downstream, it influences TGF-beta signaling by interacting with SMAD2/3 complexes, Wnt signaling via beta-catenin/TCF/LEF-mediated transcription, and the ERK1/2 and p53-BAX apoptotic pathways. This positions HDAC2 at a critical node for cell survival, proliferation, and differentiation in lung adenocarcinoma.
In A-549 cells, HDAC2 silences tumor suppressor genes and maintains dedifferentiation. CRISPR/Cas9-mediated knockout disrupts repressive complexes, causing histone and non-histone protein hyperacetylation, reactivation of cell cycle arrest and apoptotic programs, and chemosensitization. This model dissects epigenetic dependencies in non-small cell lung cancer and allows interrogation of HDAC2 roles in TGF-beta-induced epithelial-mesenchymal transition, Wnt-driven proliferation, and DNA repair. Comparing knockout and parental populations reveals functional consequences without clonal expansion.
Key applications include HDAC inhibitor screening with viability or acetylation-specific readouts, chromatin remodeling studies by ChIP-qPCR for acetylated H3 and H4, and RNA-seq to identify HDAC2-dependent gene sets. The cells support Western blotting for target and effector validation, RT-qPCR, flow cytometry for cell cycle and Annexin V apoptosis assays, and MTT proliferation tests. Epigenetic drug discovery programs can use this model for primary screening and mechanism-of-action studies. For additional technical specifications, contact Ascent Research.
